Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis

View Full Paper
Ask AI
Bookmark
Share

Authors

PLPhilip LubanskiMHMehdi Hamadani

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows graft rejection and acute graft-versus-host disease influenced by prior ruxolitinib in myelofibrosis patients.

Key Points

  • Graft rejection occurred in a significant number of patients, highlighting the risk factors associated with myelofibrosis.
  • Among 216 patients studied, 25% faced non-relapse mortality and 52.8% relapse rates post-transplantation.
  • A retrospective multicenter analysis evaluated patient outcomes using CIBMTR registry data from 2013 to 2019.
  • Future treatment in myelofibrosis may require close consideration of prior therapies and patient comorbidities for optimal outcomes.

Cite This Study

Lubanski et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e19bhttps://doi.org/10.1182/blood-2025-2460
View Full Paper
Ask AI
Bookmark
Share